Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18297062 | 1.00 | USP2 (0.39) | USP2SMN1; SMN2ESR2ADORA1NR1H2 | |
| SCHEMBL18280999 | 1.00 | USP2 (0.39) | USP2SMN1; SMN2ESR2ADORA1NR1H2 | |
| SCHEMBL18296909 | 0.86 | ESR2 (0.37) | USP2SMN1; SMN2ESR2ADORA1NR1H2 | |
| SCHEMBL18281013 | 0.86 | ESR2 (0.37) | USP2SMN1; SMN2ESR2ADORA1NR1H2 | |
| SCHEMBL18281014 | 0.86 | ESR2 (0.37) | USP2SMN1; SMN2ESR2ADORA1NR1H2 | |
| SCHEMBL15227284 | 0.83 | ADORA1 (0.41) | USP2SMN1; SMN2ESR2ADORA1NR1H2 | |
| SCHEMBL15227281 | 0.83 | ADORA1 (0.41) | USP2SMN1; SMN2ESR2ADORA1NR1H2 | |
| SCHEMBL518157 | 0.80 | USP2 (0.42) | USP2SMN1; SMN2ESR2ADORA1NR1H2 | |
| SCHEMBL23069031 | 0.79 | MEN1 (0.45) | GPR119KDM4E | |
| SCHEMBL23069032 | 0.79 | MEN1 (0.45) | GPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024937-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2022-01-27 | — | — | US | disclosed |
| US-11136328-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2021-10-05 | — | — | US | disclosed |
| US-20200299300-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2020-09-24 | — | — | US | disclosed |
| US-10584127-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (BM) | 2020-03-10 | — | — | US | disclosed |
| US-10294230-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-05-21 | — | — | US | disclosed |
| US-20180346476-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-12-06 | — | — | US | disclosed |
| US-20180170935-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-06-21 | — | — | US | disclosed |
| EP-3303323-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | Rugen Holdings (Cayman) Limited (KY) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016196513-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299300-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | USP2 3896/4885SMN1; SMN2 2666/4885ESR2 331/4885 |
| US-20180170935-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | USP2 3896/4885SMN1; SMN2 2666/4885ESR2 331/4885 |
| US-20180346476-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | USP2 3914/4885SMN1; SMN2 2635/4885ESR2 319/4885 |
| US-10294230-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | GRIN3A, GRIN1, GRIN2A | USP2 3914/4885SMN1; SMN2 2635/4885ESR2 319/4885 |
| US-20220024937-A1 | 3,3-DIFLUOROPIPERIDINE CARBAMATE HETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | USP2 3896/4885SMN1; SMN2 2666/4885ESR2 331/4885 |
| US-11136328-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | GRIN3A, GRIN1, GRIN2A | USP2 3896/4885SMN1; SMN2 2666/4885ESR2 331/4885 |
| US-10584127-B2 | 3,3-difluoropiperidine carbamate heterocyclic compounds as NR2B NMDA receptor antagonists | GRIN3A, GRIN1, GRIN2A | USP2 3896/4885SMN1; SMN2 2666/4885ESR2 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.